Japanese Journal of Ophthalmology 2004-01-01

Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis.

Minori Miyake-Kashima, Yoji Takano, Mari Tanaka, Yoshiyuki Satake, Tetsuya Kawakita, Murat Dogru, Naoko Asano-Kato, Kazumi Fukagawa, Hiroshi Fujishima

Index: Jpn. J. Ophthalmol. 48(6) , 587-90, (2004)

Full Text: HTML

Abstract

We compared the efficacy of a new nonsteroidal antiinflammatory drug (NSAID) eye drop, 0.1% bromfenac sodium (Bromfenac), with that of an antiallergic agent, 0.1% pemirolast potassium (Pemirolast), in the treatment of seasonal allergic conjunctivitis in Japanese patients.Twenty-two subjects with seasonal allergic conjunctivitis were enrolled in the study. One eye was treated with Bromfenac eye drops and the contralateral eye was treated with Pemirolast eye drops for 1 week. Subjective ocular symptoms and objective ocular signs evaluated by slit-lamp examination were scored and recorded before and after treatment.Both drugs significantly decreased ocular signs after 1 week, but not symptoms. No significant differences in subjective symptoms or objective signs were observed between the two drugs. Ten patients (45.5%) selected Bromfenac as more effective, nine patients (40.9%) selected Pemirolast, and three patients found no difference in efficacy between the two drugs.Bromfenac sodium is as safe and effective for the treatment of allergic conjunctivitis as pemirolast potassium.